The market opportunity for biosimilars is already big, but it got even bigger after the Supreme Court voted unanimously this week to remove a 180-day waiting period that’s been delaying biosimilar drug launches.
The market opportunity for biosimilars is already big, but it got even bigger after the Supreme Court voted unanimously this week to remove a 180-day waiting period that’s been delaying biosimilar drug launches.